Table 1 Association of TC2N expression with BC clinicopathological characteristics
From: TC2N inhibits distant metastasis and stemness of breast cancer via blocking fatty acid synthesis
Variable | Category | Relative TC2N expression | P | |
|---|---|---|---|---|
High (n = 94) | Low (n = 118) | |||
Age (years) | ≤ 48 | 51 | 55 | 0.269 |
|  | > 48 | 43 | 63 | |
Clinical stage (AJCC) | I | 20 | 0 | < 0.001 |
II | 47 | 33 | ||
III | 24 | 41 | ||
IV | 3 | 44 | ||
Differentiating degree | High | 21 | 10 | < 0.001 |
Moderate | 61 | 69 | ||
Low | 12 | 39 | ||
Depth of tumor invasion | T1 | 31 | 13 | < 0.001 |
T2 | 38 | 41 | ||
T3 | 24 | 51 | ||
T4 | 1 | 13 | ||
Lymph node metastasis | N0 | 38 | 27 | 0.006 |
N1-3 | 56 | 91 | ||
Distant metastasis | M0 | 91 | 77 | < 0.001 |
M1 | 3 | 41 | ||
Primary site | Left breast | 60 | 77 | 0.829 |
Right breast | 34 | 41 | ||
Disease type | Ductal BC | 81 | 100 | 0.771 |
Lobular BC | 13 | 18 | ||
Molecular subtype | Luminal A | 26 | 33 | < 0.001 |
Luminal B | 31 | 23 | ||
HER2 +  | 21 | 19 | ||
Basal-like | 16 | 43 | ||